Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hi-ClearanceROCO:1788 79 EBITDA Margin % is 14.98% as of Dec. 2025, which is 3% above its 10-year median of 14.53. GuruFocus rates ROCO:1788 with a GF Score™ of 79/100 and a GF Value™ of NT$138.61 (Fairly Valued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Hi-Clearance ranks better than 67.61% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hi-Clearance's EBITDA for the
three
months ended in Dec. 2025 was NT$164 Mil. Hi-Clearance's Revenue for the
three
months ended in Dec. 2025 was NT$1,092 Mil. Therefore, Hi-Clearance's EBITDA margin for the quarter that ended in Dec. 2025 was 14.98%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hi-Clearance EBITDA Margin % Related Terms
Hi-Clearance EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hi-Clearance's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1788 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Hi-Clearance's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hi-Clearance EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hi-Clearance's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hi-Clearance's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hi-Clearance (ROCO:1788) has a EBITDA Margin % of 14.98% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hi-Clearance and its competitors. This is near median its historical median of 14.53. Over the past decade, Hi-Clearance's EBITDA Margin % has ranged from 10.41 to 16.18. According to the industry distribution chart, Hi-Clearance ranks #264 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 32.4%.
Is Hi-Clearance's EBITDA Margin % too high?
Hi-Clearance's current EBITDA Margin % of 14.98% is near median its 10-year median of 14.53. Over the past 10 years, this metric has ranged from a low of 10.41 to a high of 16.18. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Hi-Clearance's value of 14.98% is 100.3% above this industry median. Based on the distribution chart, Hi-Clearance ranks #264 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Hi-Clearance has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hi-Clearance's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hi-Clearance ranks #264 out of 815 companies for EBITDA Margin %. This puts Hi-Clearance in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Hi-Clearance's value of 14.98% is 100.3% above this benchmark. Historically, Hi-Clearance's own EBITDA Margin % has ranged from 10.41 to 16.18 over the past decade. While the company's 10-year median is 14.53 vs. the industry median of 7.48, Hi-Clearance has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hi-Clearance's current EBITDA Margin % of 14.98% is 100.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hi-Clearance and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hi-Clearance's current EBITDA Margin % is 14.98%, which is near median its own 10-year median of 14.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hi-Clearance stock overvalued right now?
Based on GuruFocus' analysis, Hi-Clearance (ROCO:1788) is currently considered Fairly Valued. The stock's GF Value™ is NT$138.61, compared to a current price of NT$130.00 — trading 6.2% below its estimated fair value. The current EBITDA Margin % is 14.98%, which is near median its 10-year median of 14.53 and 100.3% above the Medical Devices & Instruments industry median of 7.48. Hi-Clearance's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hi-Clearance (ROCO:1788), the current EBITDA Margin % is 14.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hi-Clearance (ROCO:1788) Overvalued in 2026?
Based on GuruFocus' analysis, Hi-Clearance stock appears to be undervalued.
The current stock price of NT$130.00 is trading 6.2% below its estimated GF Value™ of NT$138.61.
GuruFocus considers Hi-Clearance to be Fairly Valued.
Key valuation signals for ROCO:1788:
EBITDA Margin %: 14.98% (near median its 10-year median of 14.53)
GF Value™: NT$138.61 vs. price of NT$130.00 (6.2% below fair value)
Industry Position: 100.3% above the Medical Devices & Instruments median (#264 of 815)
No single metric tells the full story. See the ROCO:1788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hi-Clearance Inc primary business activities involve trading medical equipment, biochemical reagents, and Western medicine. It has two segments Hemodialysis Division responsible for the procurement and distribution of a wide range of blood dialysis-related consumables, which are sold to hospitals, clinics, and distributors; and Other business segments mainly involved in selling dental materials and other products. The company generates majority of revenue from Hemodialysis Division. Its products are Single Patient Dialysis System TORAY, TORAYLIGHT Hollow Fiber Dialyzer, FILTRYZER TORAY, TORAY ETRF.
79GF Score
Get the complete analysis for ROCO:1788
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1788 has been successfully added to your 
